P1/2, N=54, Active, not recruiting, COUR Pharmaceutical Development Company, Inc. | Recruiting --> Active, not recruiting

P4, N=78, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

The present study aimed to investigate the functional role and molecular mechanisms of long intergenic non‑protein coding RNA 1117 (LINC01117) in lung adenocarcinoma (LUAD)...Actinomycin D was used to inhibit RNA transcription...In conclusion, LINC01117 may serve as a notable prognostic biomarker that promotes cell proliferation in LUAD. HOXD8 may function as a downstream target of LINC01117, with LINC01117 exerting its pro‑proliferative effects by increasing HOXD8 mRNA stability.

Integration of pharmacological evidence highlighted clinically actionable interactions between metabolic genes and FDA-approved drugs, including ASNS-asparaginase, DHODH-teriflunomide, and G6PD-rasburicase. This integrative analysis shows that cancer metabolism is altered in subtype-specific ways that can be systematically mapped to reveal potential therapeutic targets. By linking transcriptomic evidence with drug-gene interactions and clinical context, this framework provides a scalable approach for cancer metabolism research and supports the prioritization of pathways with potential translational relevance.

Intravenous injection of VDS produces the same responses as an intratumoral injection, and outperforms direct injection of H-1 parvovirus (H-1PV), which minimally affects immune responses and tumor volume. Combining bacteria and OVs creates a therapy that activates the immune system, generates antitumor immunity, and provides a promising platform for treating solid tumors.

P2, N=334, Recruiting, Centre Hospitalier Universitaire de Saint Etienne | Not yet recruiting --> Recruiting

P1, N=5, Terminated, Genprex, Inc. | Phase classification: P1/2 --> P1

P1/2, N=62, Recruiting, Genprex, Inc. | Trial primary completion date: Feb 2026 --> Jun 2026

P1, N=40, Recruiting, Moonlight Therapeutics, Inc. | Not yet recruiting --> Recruiting

Activated keratinocytes play a key role in the pathophysiology of secondary lymphedema through PAR2 by producing Th2-inducing cytokines that modulate skin inflammatory responses.

In a 4 T1 tumor-bearing mice model, LN-DMXAA(L) significantly boosted tumor growth inhibition rate to 78.3% as compared with 46.2% for LN-DMXAA(H) and 27.8% for DMXAA by activating APCs and CD8+ T cells via the STING signaling pathway. Thus, this work highlights the conception of a flexible immune-activating polysaccharide-STING agonist immunomodulator for cancer therapy.

P1, N=155, Active, not recruiting, Orca Biosystems, Inc. | N=255 --> 155